1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

30 Nov 2020
Admin
News Article

Egle Therapeutics Identifies First Novel Regulatory T-Cell Targets In Research Alliance With Takeda

Egle Therapeutics Sas (Egle), An Emerging Biotechnology Company Focused On Developing First-In Class Immunotherapies Targeting Immune Suppressor Regulatory T-Cells (Tregs) For Oncology And Autoimmune Diseases, Today Announces That It Has Achieved The First Milestone In Its Strategic Research Alliance With Takeda Pharmaceutical Company Limited (&Ldquo;Takeda&Rdquo;). In The Course Of The Strategic Research Alliance That Was Announced In June 2020, Egle Will Validate Novel Tumor-Infiltrating Regulatory T-Cell (Treg) Targets Against Which Takeda Will Develop Potential Therapies.Egle Has Leveraged Its Unique Bioinformatic And Translational Capabilities To Successfully Identify Targets That Will Now Be Pursued Under The Terms Of The Alliance. Upon Achievement Of The Target Identification, Egle Will Receive An R&Amp;D Milestone Payment And Investment From Takeda.Luc Boblet, Ceo Of Egle, Commented &Ldquo;Reaching This First Technical Milestone Marks Our Positive Progress Towards Our Joint Goal With Takeda, Of Creating The Next Generation Of Differentiated Immunotherapies Against Tregs, And Provides Strong Validation Of The Work Being Done At Egle. We Look Forward To Continuing Our Productive Alliance With Takeda While Pushing Further Our Internal Programs Through The Equity Component Of The Alliance.&Rdquo;&Ldquo;We Have Made Great Progress In Our Collaboration With Egle And Are Thrilled With The Speed Of Which We Identified Our First Novel Treg Targets,&Rdquo; Said LoÏC Vincent, Head, Oncology Drug Discovery Unit At Takeda. &Ldquo;We Hope To Build Upon This Momentum In The Next Phase Of Our Partnership To Enable And Ultimately Deliver New Immuno-Oncology Therapeutic Options.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!